Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

(RS)-MPPG

mGluR antagonist
 
ALX-550-122-M005 5 mg 48.00 USD
Do you need bulk/larger quantities?
 
Potent L-AP4-sensitive receptor antagonist.

Product Specification

Alternative Name:(RS)-α-Methyl-4-phosphonophenylglycine
 
Formula:C9H12NO5P
 
MW:245.2
 
CAS:169209-65-8
 
Purity:≥97%
 
Appearance:White solid.
 
Solubility:Soluble in dilute aqueous base.
 
Shipping:Ambient
 
Long Term Storage:+4°C
 
Handling:Protect from light.
 
ALX-550-122
Please mouse over
ALX-550-122

Product Literature References

Pharmacological agents acting at subtypes of metabotropic glutamate receptors: D.D. Schoepp, et al.; Neuropharmacology 38, 1431 (1999), Abstract;
Contribution of metabotropic glutamate receptors to the depression of excitatory postsynaptic potentials during hypoxia: A. de Mendonça & J.A. Ribeiro; Neuroreport 8, 3667 (1997), Abstract;
Antagonism of the presumed presynaptic action of L-AP4 on GABAergic transmission in the ventrobasal thalamus by the novel mGluR antagonist MPPG: T.E. Salt & J.P. Turner; Neuropharmacology 35, 239 (1996), Abstract;
Novel potent selective phenylglycine antagonists of metabotropic glutamate receptors: J.S. Bedingfield, et al.; Eur. J. Pharmacol. 309, 71 (1996), Abstract;
Pharmacological antagonism of the actions of group II and III mGluR agonists in the lateral perforant path of rat hippocampal slices: T.J. Bushell, et al.; Br. J. Pharmacol. 117, 1457 (1996), Abstract;
New phenylglycine derivatives with potent and selective antagonist activity at presynaptic glutamate receptors in neonatal rat spinal cord: D.E. Jane, et al.; Neuropharmacology 34, 851 (1995), Abstract;

Related Literature

Brochures
Essential Research Tools for Neurodegeneration & Neural Signaling
Essential Research Tools for Neurodegeneration & Neural Signaling
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,